Combination therapy with oleanolic acid and metformin as a synergistic treatment for diabetes

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Wang, Xue ^a   Chen, Yupeng ^a   Abdelkader, Daoud ^a   Hassan, Waseem ^a   Sun, Hongbin ^a   Liu, Jun ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; CHOLESTEROL; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER 2; GLYCOGEN PHOSPHORYLASE; GLYCOGEN SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; OLEANOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PHOSPHOENOLPYRUVATE CARBOXYKINASE 1; PROTEIN KINASE B; TRANSDUCER OF REGULATED CREB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; RNA;

ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; FLUID INTAKE; FOOD INTAKE; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCOGEN LIVER LEVEL; GLYCOGEN SYNTHESIS; GLYCOGENOLYSIS; HEPATITIS; IMMUNOREACTIVITY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER; LIVER CELL; LIVER WEIGHT; MALE; MONOTHERAPY; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; WEIGHT GAIN; ANIMAL; C57BL MOUSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG COMBINATION; HOMEOSTASIS; HYPOGLYCEMIA; METABOLISM; ORGAN SIZE; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; BIOMARKERS; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GLUCOSE; HOMEOSTASIS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; MALE; METFORMIN; MICE; MICE, INBRED C57BL; OLEANOLIC ACID; ORGAN SIZE; PHOSPHORYLATION; RNA;

EID: 84924253968     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/973287     Document Type: Article

References (38)

1. B. Paulweber, P.Valensi, J. Lindstr,N. M. Lalic, andC. J.Greaves, "Europe evidence-based guidline for the prevention of type 2 diabetes," Hormone and Metabolic Research, vol. 42, supplement 1, pp. S3-S36, 2010.
2. R. A. DeFronzo, D. Simonson, and E. Ferrannini, "Hepatic and peripheral insulin resistance: a common feature of Type 2 (noninsulin-dependent) and Type 1 (insulin-dependent) diabetes mellitus," Diabetologia, vol. 23, no. 4, pp. 313-319, 1982.
3. C. Postic, R. Dentin, and J. Girard, "Role of the liver in the control of carbohydrate and lipid homeostasis," Diabetes and Metabolism, vol. 30, no. 5, pp. 398-408, 2004.
4. D. M. Nathan, J. B. Buse, M. B. Davidson, and et al, "Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes," Diabetes Care, vol. 32, no. 3, pp. 193-203, 2009.
5. M. Foretz, S. Hébrard, J. Leclerc et al., "Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state," The Journal of Clinical Investigation, vol. 120, no. 7, pp. 2355-2369, 2010.
6. X. A. Wen, P. Zhang, J. Liu et al., "Pentacyclic triterpenes. Part 2: synthesis and biological evaluation of maslinic acid derivatives as glycogen phosphorylase inhibitors," Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 3, pp. 722-726, 2006.
7. J. Liu, H. Sun, W. Duan, D. Mu, and L. Zhang, "Maslinic acid reduces blood glucose in KK-Ay mice," Biological and Pharmaceutical Bulletin, vol. 30, no. 11, pp. 2075-2078, 2007.
8. J. Liu, H. B. Sun, X. F. Wang, D. Mu, H. Liao, and L. Zhang, "Effects of oleanolic acid and maslinic acid on hyperlipidemia," Drug Development Research, vol. 68, no. 5, pp. 261-266, 2007.
9. J. Chen, J. Liu, L. Zhang et al., "Pentacyclic triterpenes. Part 3: synthesis and biological evaluation of oleanolic acid derivatives as novel inhibitors of glycogen phosphorylase," Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 11, pp. 2915-2919, 2006.
10. J. Liu,T.He, Q. Lu, J. Shang,H. B. Sun, and L. Y. Zhang, "Asiatic acid preserves beta cell mass and mitigates hyperglycemia in streptozocin-induced diabetic rats," Diabetes/Metabolism Research and Reviews, vol. 26, no. 6, pp. 448-454, 2010.
11. L. Y. Zhang, J. Chen, Y. C. Gong, J. Liu, W. Hua, and H. Sun, "Synthesis and biological evaluation of asiatic acid derivatives as inhibitors of glycogen phosphorylases," Chemistry & Biodiversity, vol. 6, no. 6, pp. 864-874, 2009.
12. X. Wen, H. Sun, J. Liu et al., "Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystallographic studies," Journal ofMedicinal Chemistry, vol. 51,no. 12,pp. 3540-3554, 2008.
13. J. Liu, "Pharmacology of oleanolic acid and ursolic acid," Journal of Ethnopharmacology, vol. 49, no. 2, pp. 57-68, 1995.
14. J. Liu, "Oleanolic acid and ursolic acid: research perspectives," Journal of Ethnopharmacology, vol. 100, no. 1-2, pp. 92-94, 2005.
15. P.Dzubak, M.Hajduch, D. Vydra et al., "Pharmacological activities of natural triterpenoids and their therapeutic implications," Natural Product Reports, vol. 23, no. 3, pp. 394-411, 2006.
16. L. Z. Xu and Z. X. Wan, "The effect of oleanolic acid on acute hepatitis (70 cases)," Humane Medicine, vol. 7, pp. 50-52, 1980.
17. S. L. Xu, "Effects of oleanolic acid on chronic hepatitis: 188 case reports," in Symposium on Oleanolic Acid, pp. 23-25, 1985.
18. D. M. Minich, J. S. Bland, J. Katke et al., "Clinical safety and efficacy of NG440: a novel combination of rho iso-alpha acids from hops, rosemary, and oleanolic acid for inflammatory conditions," Canadian Journal of Physiology and Pharmacology, vol. 85, no. 9, pp. 872-883, 2007.
19. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor,D. F. Treacher, and R. C. Turner, "Homeostasis model assessment: insulin resistance and cell function from fasting plasma glucose and insulin concentrations in man," Diabetologia, vol. 28, no. 7, pp. 412-419, 1985.
20. R. D. Lillie and J. Greco, "Malt diastase and ptyalin in place of saliva in the identification of glycogen," Biotechnic & Histochemistry, vol. 22, no. 2, pp. 67-70, 1947.
21. N. Wollen and C. J. Bailey, "Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin," Biochemical Pharmacology, vol. 37, no. 22, pp. 4353-4358, 1988.
22. X. Wang, X.-L. Ye, R. Liu et al., "Antioxidant activities of oleanolic acid in vitro: possible role of Nrf2 and MAP kinases," Chemico-Biological Interactions, vol. 184, no. 3, pp. 328-337, 2010.
23. X.Wang, Y.-L. Li, H.Wu et al., "Antidiabetic effect of oleanolic acid: a promising use of a traditional pharmacological agent," Phytotherapy Research, vol. 25, no. 7, pp. 1031-1040, 2011.
24. P. S. Ngubane, B. Masola, and C. T. Musabayane, "The effects of syzygium aromaticum-derived oleanolic acid on glycogenic enzymes in streptozotocin-induced diabetic rats," Renal Failure, vol. 33, no. 4, pp. 434-439, 2011.
25. K. Sharma, P.McCue, and S. R. Dunn, "Diabetic kidney disease in the db/dbmouse,"TheAmerican Journal of Physiology-Renal Physiology, vol. 284, no. 6, pp. 1138-1144, 2003.
26. K. S. Oh, E. Y. Kim, M. Yoon, and C. M. Lee, "Swim training improves leptin receptor deficiency-induced obesity and lipid disorder by activating uncoupling proteins," Experimental and Molecular Medicine, vol. 39, no. 3, pp. 385-394, 2007.
27. N.Ghilardi, S. Ziegler, A. Wiestner, R. Stoffel, M. H. Heim, and R. C. Skoda, "Defective STAT signaling by the leptin receptor in diabetic mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 13, pp. 6231-6235, 1996.
28. S. Chandran, F. Yap, and K. Hussain, "Molecular mechanisms of protein induced hyperinsulinaemichypoglycaemia," World Journal of Diabetes, vol. 5, no. 5, pp. 666-677, 2014.
29. T. Pelikánová, "Insulin resistance-its causes and therapy possibilities," Vnitrn Lekarstv, vol. 60, no. 9, pp. 746-755, 2014.
30. L. Agius, "Physiological control of liver glycogen metabolism: lessons from novel glycogen phosphorylase inhibitors," Mini-Reviews in Medicinal Chemistry, vol. 10, no. 12, pp. 1175-1187, 2010.
31. N. Gaboriaud-Kolar and A.-L. Skaltsounis, "Glycogen phosphorylase inhibitors: a patent review (2008-2012)," Expert Opinion on Therapeutic Patents, vol. 23, no. 8, pp. 1017-1032, 2013.
32. J. C. Hutton and R. M. O'Brien, "Glucose-6-phosphatase catalytic subunit gene family," The Journal of Biological Chemistry, vol. 284, no. 43, pp. 29241-29245, 2009.
33. D. Stapleton, K. I.Mitchelhill, G. Gao et al., "Mammalian AMPactivated protein kinase subfamily," The Journal of Biological Chemistry, vol. 271, no. 2, pp. 611-614, 1996.
34. A.Woods, P. C. F. Cheung, F. C. Smith et al., "Characterization of AMP-activated protein kinase and subunits: assembly of the heterotrimeric complex in vitro," The Journal of Biological Chemistry, vol. 271, no. 17, pp. 10282-10290, 1996.
35. W. W. Winder and D. G. Hardie, "Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise," The American Journal of Physiology-Endocrinology and Metabolism, vol. 270, no. 2, pp. E299-E304, 1996.
36. E. Hajduch, G. J. Litherland, and H. S. Hundal, "Protein kinase B (PKB/Akt)-a key regulator of glucose transport" FEBS Letters, vol. 492, no. 3, pp. 199-203, 2001.
37. E. Sarnowska, A. Balcerak,M. Olszyna-Serementa, D. Kotlarek, T. J. Sarnowski, and J. A. Siedlecki, "Amp-activated protein kinase (AMPK) as therapeutic target," Postpy Higieny i Medycyny Doswiadczalnej, vol. 67, pp. 750-760, 2013.
38. A. R. Aroor, S.McKarns, V. G.Demarco, G. Jia, and J. R. Sowers, "Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance,"Metabolism: Clinical and Experimental, vol. 62, no. 11, pp. 1543-1552, 2013.